Get the Stockscreener App
3.04
1.33%
0.04
Pre-market:
3.09
0.05
+1.64%
Nrx Pharmaceuticals Inc stock is traded at $3.04, with a volume of 1.33M.
It is up +1.33% in the last 24 hours and up +38.18% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.00
Open:
$3.06
24h Volume:
1.33M
Relative Volume:
1.62
Market Cap:
$100.53M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-1.9366
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
+3.05%
1M Performance:
+38.18%
6M Performance:
+14.29%
1Y Performance:
+49.75%
1-Day Range:
$3.0282
$3.21
1-Week Range:
$2.85
$3.21
52-Week Range:
$1.62
$3.84
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.04 | 100.53M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital - Moomoo
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
Amid ketamine shortages, NRx begins making a preservative-free U.S. version - Stock Titan
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine - Yahoo Finance
NRXP Stock Price, Quote & Chart | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short Interest - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) surpasses Q4 earnings estimates - MSN
NRx Reports FDA Feedback, Progress on Ketamine Application - MyChesCo
Equities Analysts Offer Predictions for NRXP Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
NRXP Forecast, Price Target & Analyst Ratings | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals (NASDAQ:NRXP) Earns "Buy" Rating from HC Wainwright - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $49.00 at Ascendiant Capital Markets - MarketBeat
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating on FDA progress - Investing.com
H.C. Wainwright reiterates NRx Pharmaceuticals stock rating on FDA progress By Investing.com - Investing.com India
NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree - MSN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - Scott Coop
Positive FDA Response on Preservative-Free Ketamine After President Trump Orders Accelerated Approval for Psychedelic Medication Developers Including NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress - Barchart.com
NRx Pharmaceuticals receives FDA positive review for ketamine ANDA By Investing.com - Investing.com India
NRXP (NRX Pharmaceuticals Inc.) posts wider than expected Q4 2025 loss even as shares rise modestly today.Earnings Season - Cổng thông tin điện tử tỉnh Tây Ninh
NRX Pharmaceuticals (NRXP) Sector Rotation | Q4 2025: Earnings Fall ShortProfessional Trade Ideas - Xã Thanh Hà
NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock Price Today & Analysis - Gotrade
Positive FDA Response on Preservative-Free Ketamine After - openPR.com
NRx Pharmaceuticals receives FDA positive review for ketamine ANDA - Investing.com
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program - The Manila Times
NRXP Financials: Income Statement, Balance Sheet & Cash Flow | Nrx Pharmaceuticals Inc - Stock Titan
FinancialContentPresidential Executive Order to Accelerate Approval of Psychedelic Medications; Those Being Developed by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRXP Ownership | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer - MyChesCo
NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History - Yahoo Finance
NRx Re-Files FDA Application for Preservative-Free IV Ketamine - MSN
NRx Pharmaceuticals Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality - Investing News Network
NRx Pharmaceuticals (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development - The Globe and Mail
NRx Pharmaceuticals welcomes the newly-signed Executive Order - TipRanks
NRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at D. Boral Capital - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality - ChartMill
NRx says FDA finds no bioequivalence issues in ketamine filing - MSN
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications - Investing News Network
User - The Chronicle-Journal
NRx Pharmaceuticals forms defense R&D subsidiary By Investing.com - Investing.com Australia
AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP) - WFMZ.com
NRx Pharmaceuticals (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications - Barchart
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):